clinical trial · NCT04821063
Placebo-Corrected Effects of Therapeutic Dose (100 mg) and Supratherapeutic Dose (300 mg) of ITF2357 (Givinostat) and Moxifloxacin on QT/QTC Interval
Italfarmaco·phase1·completed·n = 31
Duchenne and Becker Muscular DystrophyPolycytemia VeraITF2357 10 mg/mLITF2357 10 mg/mLPlaceboMoxifloxacin HydrochloridePlacebo
brief summary
The study will evaluate the effect of a therapeutic dose and a supratherapeutic dose of ITF2357 on the QT/QTc interval.
started
Apr 13, 2021
primary completion
Jun 18, 2021
completion
Jun 18, 2021
last updated
Jan 11, 2024
official title
A Randomized, Partially Double-Blind, Four-Period, Four-Treatment, Crossover Study Investigating the Placebo-Corrected Effects of a Therapeutic Dose (100 mg) and a Supratherapeutic Dose (300 mg) of ITF2357 (Givinostat) and Moxifloxacin on QT/QTC Interval in Healthy Male and Female Subjects
sourced from ClinicalTrials.gov · pharmadog mirrors structured fields, not the full protocol